New Product Launch at CellGenix

April 2017

Preclinical Recombinant Human Interferon-gamma (rh IFN-γ)


 

CellGenix proudly announces the launch of E.coli derived Recombinant Human Interferon-gamma.

This new preclinical product will expand CellGenix’s product portfolio and can be used in several areas of application.

 

Features

   ›  E.coli derived; Human sequence

     High purity

     Thermostability up to 50°C as lyophilized product

     Batch specific Certificate of Analysis

     ADCF Level 2 (No ADC in product and production process)

 

Areas of Application

     Ex vivo maturation of dendritic cells (monocyte derived)

     Ex vivo generation of cytokine induced killer cells (CIK)

     Stimulation of monocytes, macrophages, and microglia

 

Intended Use

For preclinical ex vivo use. Not intended for therapeutic use.

 

Detailed product information

 

From Research to ATMP - Your Dedicated Partner in Cell Therapy